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DOI 10.1186/s13058-014-0477-8RESEARCH ARTICLE Open AccessHormone metabolism pathway genes and
mammographic density change after quitting
estrogen and progestin combined hormone
therapy in the California Teachers Study
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Anna H Wu1, Leslie Bernstein2 and Giske Ursin1,3,4Abstract
Introduction: Mammographic density (MD) is a strong biomarker of breast cancer risk. MD increases after women
start estrogen plus progestin therapy (EPT) and decreases after women quit EPT. A large interindividual variation in
EPT-associated MD change has been observed, but few studies have investigated genetic predictors of the
EPT-associated MD change. Here, we evaluate the association between polymorphisms in hormone metabolism
pathway genes and MD changes when women quit EPT.
Methods: We collected mammograms before and after women quit EPT and genotyped 405 tagging single nucleotide
polymorphisms (SNPs) in 30 hormone metabolism pathway genes in 284 non-Hispanic white participants of the California
Teachers Study (CTS). Participants were ages 49 to 71 years at time of mammography taken after quitting EPT. We
assessed percent MD using a computer-assisted method. MD change was calculated by subtracting MD of an ‘off-EPT’
mammogram from MD of an ‘on-EPT’ (that is baseline) mammogram. Linear regression analysis was used to investigate
the SNP-MD change association, adjusting for the baseline ‘on-EPT’ MD, age and BMI at time of baseline mammogram,
and time interval and BMI change between the two mammograms. An overall pathway and gene-level summary was
obtained using the adaptive rank truncated product (ARTP) test. We calculated ‘P values adjusted for correlated tests
(PACT)’ to account for multiple testing within a gene.
Results: The strongest associations were observed for rs7489119 in SLCO1B1, and rs5933863 in ARSC. SLCO1B1 and
ARSC are involved in excretion and activation of estrogen metabolites of EPT, respectively. MD change after quitting
was 4.2% smaller per minor allele of rs7489119 (P = 0.0008; PACT = 0.018) and 1.9% larger per minor allele of rs5933863
(P = 0.013; PACT = 0.025). These individual SNP associations did not reach statistical significance when we further used
Bonferroni correction to consider the number of tested genes. The pathway level summary ARTP P value was not
statistically significant.
Conclusions: Data from this longitudinal study of EPT quitters suggest that genetic variation in two hormone
metabolism pathway genes, SLCO1B1 and ARSC, may be associated with change in MD after women stop using EPT.
Larger longitudinal studies are needed to confirm our findings.* Correspondence: leee@usc.edu
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Mammographic density (MD) is a measure of the amount
of epithelium and stroma relative to the amount of fat tis-
sue in the breast. MD is one of the strongest biomarkers
of breast cancer risk [1] and is associated with a number
of breast cancer risk factors [2]. Combined estrogen plus
progestin therapy (EPT) is an established risk factor of
breast cancer [3-9]. Data from a randomized clinical trial,
the Women’s Health Initiative (WHI), confirmed that an
EPT regimen consisting of conjugated equine estrogens
(CEE) and medroxyprogesterone acetate (MPA) [9] in-
creased breast cancer risk. EPT use has also been asso-
ciated with a substantial increase in MD, by 3 to 5% in the
Postmenopausal Estrogen/Progestin Interventions (PEPI)
trial, depending on the regimen [10,11], and by approxi-
mately 7% in the WHI trial [12]. In both studies, a large
interindividual variation was observed [10-12]. In the PEPI
trial, approximately 20% of women in the EPT group
experienced a one-step increase in BI-RADS grade, which
represents 14 to 18% increase in density [10]. This
enormous change was not observed in others in the EPT
group, but some increase was observed in a larger number
of women [10,11]. Importantly, the increase in MD was
positively correlated with post-treatment increases in se-
rum levels of estrone (E1) [13], estrone sulfate (E1S) [14],
and progestogen levels [15]. These findings suggest that
genetic factors influencing absorption and metabolism of
EPT may be important in predicting EPT-associated MD
change.
Similarly, MD decreases after discontinuing hormone
therapy [16,17]. In a randomized trial of short-term ces-
sation of hormone therapy, MD significantly decreased
in the EPT cessation group, but with an interindividual
variation in MD decrease [17,18]. In the EPT cessation
group, MD decreased by ≥7.5% in 24% of women; de-
creased by 3% to <7.5% in another 24%; changed little
(<3%) in 30%; and increased by >3% in 23% [18]. None
of the measured lifestyle factors modified the magnitude
of the MD decrease, and the authors concluded that
genetic factors could be important determinants. Con-
sidering that increases in MD are associated with higher
breast cancer risk [19] and that decreases in MD are as-
sociated with reduced breast cancer risk [19,20], identi-
fying genetic determinants of MD change associated
with EPT use and quitting is important to understand
breast cancer risk in current or former EPT users.
While there have been efforts to identify genetic deter-
minants of MD in large cross-sectional samples [21,22],
few studies have investigated the genetic predictors of lon-
gitudinal MD changes associated with EPT use. In a small
sample from a clinical trial of EPT use where four single
nucleotide polymorphisms (SNPs) in four hormone path-
way genes were investigated, two SNPs (Val432Leu in
CYP1B1 and L311V in AKR1C4) were associated withMD change after starting EPT [23]. A longitudinal study
based on the European Prospective Investigation into
Cancer and Nutrition (EPIC) cohort suggested that gen-
etic variation in progesterone receptor gene (PGR) modi-
fied the effect of hormone therapy on MD change [24].
Data from the PEPI trial did not support this association:
none of the 23 tested tagging SNPs in the PGR were
associated with MD change in EPT treatment arms [15].
Each of these studies investigated less than five genes
[15,23,24], and only the PEPI study genotyped more than
two SNPs in each gene [15]. In the current study, we
investigated the association between 405 SNPs in 30 hor-
mone metabolism pathway genes and MD change after
stopping EPT use using data from the California Teachers
Study (CTS) mammographic density subcohort.
Materials and methods
California Teachers Study (CTS)
The CTS is a prospective cohort of 133,479 current and
former female public school teachers and other public
school professionals, who were members of the California
State Teachers Retirement System in 1995. At baseline,
cohort participants completed a mailed questionnaire pro-
viding detailed information on reproductive history, oral
contraceptive use, hormone therapy use and personal
medical history including any previous diagnosis of can-
cer. A detailed description of the CTS is available [25].
The CTS was approved by the Institutional Review Board
at each collaborating institution: the Cancer Prevention
Institute of California, the University of California, Irvine,
the University of Southern California, and the City of
Hope in accord with assurances filed with and approved
by the US Department of Health and Human Services.
Mammographic density substudy
The CTS mammographic density substudy was con-
ducted to evaluate the role of genetic polymorphisms on
MD changes occurring after women initiate or stop
using EPT. We selected 1,420 women from among those
who responded to a follow-up questionnaire collected
around 2000 to 2001 and who were aged 40 to 60 years
at cohort enrollment, lived in California and had not
had a cancer diagnosis since enrolling in the study,
newly initiated EPT use during the interval between en-
rollment and completion of the third questionnaire col-
lected around 2000 to 2001, had a mammogram in the
past two years, and were not participating in another
CTS substudy. These initial selection criteria were used
to recruit women who were most likely to have had re-
cent mammograms before and after they started EPT
use. Characteristics of the 1,420 women who were se-
lected are described in Additional file 1. Since it was
assumed that many in the CTS stopped using EPT fol-
lowing the publication of WHI results in June 2002 [26],
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to identify women who had mammograms before and
after they quit EPT. We sent out letters to 1,420 CTS
participants to solicit participation in this mammogram
substudy and to inform women we would be contacting
them by telephone. We spoke with 1,272 women
(89.6%), and identified 21 women who were ineligible
for this study (seven with a previous cancer diagnosis
and 14 who did not meet the mammography screening
criterion). Of the 1,251 eligible women, 247 women did
not participate in this mammographic density substudy.
Reasons for non-participation were refusals (n = 111),
not providing written informed consent (n = 134), with-
drawal of consent (n = 1), and not completing telephone
interview (n = 1); a total of 1,004 women were included
in the study. We conducted a telephone interview with
eligible participants to obtain updated information on
menstrual history and hormone use. We collected mam-
mograms for 993 of the 1,004 women, and excluded 29
because we could not determine whether they were
using hormone therapy at the time of mammogram. On
average, eight mammograms for each participant were
available to us. Some mammography facilities enclosed
information on menstrual history and hormone use of
each woman at the time of each mammogram. This infor-
mation was available for approximately 50% of all partici-
pants and for approximately 40% of their mammograms.
When we compared this information with the interview-
based hormone therapy information, approximately 40%
of these women had some inconsistency in the years of
hormone therapy use between the two data sources.
About 67% of the inconsistencies was due to ±1 year dif-
ference in the year when they started or stopped using
hormone therapy; several years of difference were noted
in other women. We considered the information collected
from medical records at the time of mammography to be
more accurate than women’s recall at the time of study
enrollment (telephone interview), and therefore used the
information from the mammography facilities when avail-
able. The mammographic density substudy of the CTS
was approved by the University of Southern California in-
stitutional review board, and all participants provided
written informed consent.
Selection of mammograms
To determine MD changes following the changes in
women’s EPT use, we intended to select one ‘on-EPT
mammogram’ taken while the participant was using EPT
and one ‘off-EPT mammogram’ taken while the partici-
pant was not using any type of hormone therapy, either
EPT or ET. Many EPT users in the CTS quit EPT use
after the publication of WHI results in June 2002 [26]. We
also realize that many women cannot recall exactly when
they stopped hormone therapy. We therefore decided toselect the on-EPT mammogram that was taken before July
1 2002, to minimize misclassification of EPT use status.
When selecting off-EPT mammograms, we preferred
mammograms that were taken after 2003. The implication
was that we would mostly measure MD changes after
‘stopping’ EPT use rather than changes after ‘starting’ EPT
use. Second, it has been shown that EPT-related MD
changes occur predominantly within the first 12 months
after starting EPT use and remain constant for at least the
next two years [10]. Therefore, we preferred to select off-
EPT mammograms taken as close as possible to the year
of on-EPT mammograms but with at least a one-year
interval between the on-EPT and off-EPT mammograms.
After applying these criteria, we selected on-EPT mam-
mograms of 578 women and off-EPT mammograms of
757 women. Both an on-EPT mammogram and an off-
EPT mammogram were available for 422 women, com-
prising the longitudinal set of this mammogram substudy.
Construction of EPT quitters’ dataset
Of the 422 in the longitudinal set, 371 women were quit-
ters, and 51 women were starters. Many women start
using EPT during their menopausal transition, when
ovarian estrogen levels are decreasing but are not as low
as in postmenopausal women [27,28]. It is possible that
off-EPT mammograms of some EPT starters were taken
while they were still undergoing the menopausal transi-
tion, although women reported that they were postmen-
opausal at that time. In such cases, the measurement of
MD change before and after starting EPT use (that is
increasing hormone levels) would be complicated by the
MD change associated with the menopausal transition
(that is decreasing hormone levels). Upon inspection of
the menopausal status data for the starters, we could not
exclude the possibility that the off-EPT mammogram of
the majority of the starters were taken before they be-
came completely postmenopausal. If this was the case,
the data from these starters are likely to measure a de-
cline in MD when going from a pre- or perimenopausal
off-EPT state to a postmenopausal state on EPT, rather
than to measure an increase in MD when going from a
postmenopausal off-EPT state to a postmenopausal on-
EPT state. Therefore, we decided to restrict the current
study to the 371 EPT quitters in the longitudinal set.
Mammographic density assessment
The methods for MD measurements used for this study
have been described previously [11,13]. We digitized the
images using a Cobrascan CX812T scanner (Radiographic
Digital Imaging, Torrance, CA, USA) at a resolution of
150 pixels/inch (59 dots/cm). MD was assessed by one of
the authors (GU) on scanned images using the USC
Madena method, a validated computer-assisted, quantita-
tive technique [10]. The total area of the breast was
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percent mammographic density, was calculated as the
absolute density divided by the total area of the breast (as
a percent). Readers were blinded to EPT use and which
mammograms belonged to the same patient. We esti-
mated change in MD by subtracting MD of off-EPT mam-
mogram from that of on-EPT mammogram. For quality
assurance, we included random blinded duplicates of 183
mammograms. Correlation between duplicate MD mea-
sures was excellent (R = 0.96).
Specimen collection and DNA extraction
We mailed an Oragene DNA self-collection kit (DNA
Genotek, Kanata, ON, Canada) to the participant and re-
turn postage-paid mailing materials. Of the 371 women
eligible for the current study, 328 women provided suffi-
cient amount of samples for DNA extraction. We ex-
tracted DNA using the Oragene protocol (DNA Genotek).
Tagging SNP selection and genotyping
We used the same tagging SNPs selected for a CTS-nested
case-control study of breast cancer [29]. Briefly, we selected
linkage disequilibrium (LD) tagging SNPs across each gene,
20 kb upstream of 5′ untranslated region (UTR) and 10 kb
downstream of 3′ UTR, using the Snagger software [30]
and the TagSNPs program [31,32]. We aimed to capture
all common SNPs (minor allele frequency (MAF) of at
least 5%) in whites with minimum pairwise r2 of at least
0.80. For some genes, due to space limitation of our geno-
typing platform, we included a few selected SNPs instead
of complete lists of tagging SNPs.
Genotyping of the selected 455 SNPs were performed
using the Illumina Golden Gate Assay (Illumina, Inc.,
San Diego, CA, USA) in the University of Southern
California Core Facility. We excluded 38 SNPs with a call
rate <90%, five SNPs with Hardy-Weinberg equilibrium
P value <0.001, and seven SNPs with MAF < 1%, leaving
405 SNPs for analyses. About 6% of the 328 genotyped
samples (n = 19) had a genotyping success rate (call rate)
of less than 90% and were excluded from the analyses.
The majority of the remaining 309 samples were non-
Hispanic whites (n = 284). Due to the small sample size of
women in other ethnic groups, we restricted the analysis
to 284 non-Hispanic whites. The genotyping concordance
rate was >99.9% based on 15 duplicate samples with a call
rate >90%.
Statistical analysis
We used linear regression to examine the association
between genotype and change in MD (that is ‘on-EPT
density’ minus ‘off-EPT density’), adjusting for age and
body mass index (BMI) (kg/m2) at on-EPT mammo-
gram, time interval and BMI change between the two
mammograms, and ‘on-EPT density’. These adjustmentvariables were chosen because age and BMI are strong de-
terminants of MD [1], and baseline MD could be related
to the absolute level of MD decrease [18]. An additive
genetic model was used, which estimate the difference in
the outcome variable (that is change in MD) per copy of
the minor allele of each SNP (that is modeled as 0, 1, or 2
copies of the minor allele). The individual SNP P values
were corrected for multiple testing within each gene using
the PACT method [33], which takes into account corre-
lation due to LD. In order to capture gene and pathway
level effects that may not be detectable through any single
SNP, we also performed gene-based and pathway-based
tests using the adaptive rank truncated product (ARTP)
method [34]. ARTP adaptively combines single SNP
P values within a gene region or a pathway to obtain a
single test statistic for the gene or pathway and assesses
significance of the test by a permutation procedure. Unlike
a multiple testing procedure like PACT, which accounts for
multiple SNP tests in order to properly control the type I
error, ARTP combines information across SNPs within a
gene or a pathway in order to increase the power to detect
a gene or pathway level effect.
Imputation
For a gene region that contains the most significant fin-
ding, we imputed genotype data for all SNPs reported in
the 1000 Genomes project [35]. As the reference panel,
we used the haplotypes of 1,092 samples (all popula-
tions) from the release version 3 of the 1000 Genomes
Project Phase I [35]. Combining reference data from all
populations helps improve imputation accuracy of low-
frequency variants [36]. The haplotypes were phased
using SHAPEIT2 [37]. We imputed genotypes in the se-
lected gene region to the 1000 Genomes reference panel
using IMPUTE2 [38]. We used the ‘certainty’ and ‘info’
metrics as the imputation quality measure, with cut-
points of >0.9 and >0.5 for each metric, respectively. We
also excluded imputed SNPs with MAF < 0.01. We used
the genotype probabilities in a dosage format as opposed
to the best genotype calls in the association tests.
Parity induces substantial proliferation, differentiation,
and subsequent involution of breast tissue cells [39]. It is
known that nulliparous women have higher MD than par-
ous women [40,41], and that the association between MD
and breast cancer risk may be stronger in nulliparous
women than in parous women [42]. Therefore, we con-
ducted exploratory analyses stratified by parity. Statistical
tests for interaction were evaluated by introducing pro-
duct terms with genotype and conducting Wald tests. We
also conducted a subgroup analysis restricted to women
who were aged 56 or older at time of on-EPT mammo-
gram. This analysis helps to exclude the possibility that
the genotype-MD change association is mainly driven by
the MD changes related to menopausal transition rather
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based US study, >97% of those with natural menopause
were postmenopausal by age 56 years [7]. Longitudinal
data from the Minnesota Breast Cancer Family Study also
suggest that non-hormone users show large decline in
MD until her early 50s, and the age-related decline slows
down from her late 50s [43]. We also performed subgroup
analyses and statistical tests of interaction by baseline BMI
(<25 kg/m2, ≥25 kg/ m2) and BMI change (<±1 kg/m2,
greater than 1 kg/m2 increase or decrease in BMI) bet-
ween the two mammograms.
Results
Women who were included in the final analysis (284
non-Hispanic white EPT quitters) were similar to those
interviewed but not included in the analysis with respect
to several factors except menopausal status (Table 1).
Those included in the analysis were more likely to be
peri- or postmenopausal at cohort enrollment. The time
interval between the two mammograms was ≤3 years for
about 50% of the 284 EPT quitters, and >3 to 5 years for
another 37% (Table 1). Mean (± standard deviation (SD)) of
the MD change between the two mammograms was 4.0%
(±7.0%). The absolute amount of MD decrease was posi-
tively associated with baseline age (regression coefficient =
0.20, P = 0.04), baseline BMI (regression coefficient = 0.19,
P = 0.016), baseline MD (regression coefficient = 0.17,
P < 0.0001), longer time interval (regression coefficient =
0.43, P = 0.078), and larger BMI increase (regression coef-
ficient = 0.46, P = 0.056) between the two mammograms,
when all of these variables were included in the regression
model.
The overall ARTP test for the entire set of 405 SNPs
in the hormone metabolism pathway genes was not sta-
tistically significant (P = 0.49; data not shown). When we
applied this method to each gene separately, the gene-
level ARTP test P values were 0.02 and 0.04, respec-
tively, for ARSC and SLCO1B1 (Table 2), suggesting that
genetic variation in ARSC and SLCO1B1 may be asso-
ciated with EPT-associated MD change. However, when
we considered the number of genes tested and applied
a Bonferroni correction, these gene-level ARTP test
P values were not statistically significant.
When we tested the association between MD and each
individual SNP, only two SNPs, rs7489119 in SLCO1B1
and rs5933863 in ARSC, showed statistically significant
associations after correcting for multiple testing within
each gene (Table 3). The MD decrease after quitting
EPT was 4.2% smaller per minor allele (A allele) of
rs7489119 (in SLCO1B1). The least squares mean of MD
change for CC genotype carriers was 4.5% (that is 4.5%
decrease in MD after quitting EPT), adjusted for the co-
variates described in the Materials and Methods section.
In contrast, the least squares mean for the CA or AAgenotype carriers was −0.2% (that is 0.2% increase in
MD after quitting EPT; data not shown). When we per-
formed association tests for 575 imputed SNPs in the
SLCO1B1 region, only rs79640916 and rs78854974 were
associated with MD change with P values of 0.0006 and
0.0007 (not corrected for multiple testing), respectively.
Rs79640916 and rs78854974 are located in the intron
regions of SLCO1B1, 23 kb and 40 kb away from
rs7489119, and in LD with rs7489119 (r2 = 0.65 for both
SNPs) in European populations based on 1000 Genomes
data [35]. None of the other imputed SNPs were associa-
ted with MD change with a P value <0.001 (Additional
file 2).
For rs5933863 (ARSC), the MD decrease after quitting
EPT was 1.9% larger per minor allele (A allele) (Table 3).
The least squares means for GG carriers was 3.4% while
it was 5.7% for GA or AA carriers (data not shown). In
other words, GG carriers had 3.4% decrease in MD after
quitting EPT, and GA or AA carriers had 5.7% decrease
in MD after quitting EPT. However, if we further applied
Bonferroni corrections considering the number of genes
tested, none of these associations remained statistically
significant. The results for all investigated SNPs are pre-
sented in Additional file 3.
In our exploratory subset analysis restricted to 64 nul-
liparous women, rs2077647 in ESR1 and rs9605030 in
COMT were associated with EPT-related density changes,
which remained statistically significant after correcting for
multiple testing at the gene level (both PACT < 0.05;
Table 4). The minor allele of rs2077647 was associated
with 3.9% larger density decrease after quitting EPT. The
minor allele of rs9605030 was associated with 4.5% larger
density decrease after quitting EPT. P values for inter-
action with parity for these two SNPs were 0.003 and
0.011, respectively (uncorrected for multiple testing).
Among 219 parous women, only rs5933863 in ARSC
had a gene-level PACT <0.05, but this SNP showed simi-
lar magnitude of association with MD change in nul-
liparous women (P for interaction = 0.82; Table 4).
When the analysis was restricted to women who were
aged 56 or older at the time of their on-EPT mammogram
(n = 143), the association with rs7489119 (SLCO1B1) be-
came stronger: the minor allele of rs7489119 was associ-
ated with 6.2% smaller density decrease after quitting EPT
(P = 0.0003; PACT = 0.007; data not shown). The asso-
ciation with rs5933863 (ARSC) was similar in magnitude,
although this association was not statistically significant
(PACT >0.05; data not shown).
EPT-related MD changes occur predominantly within
the first 12 months after starting EPT use and remain
rather constant for at least the next two years [10].
When we excluded 15 women whose on-EPT mam-
mogram was taken within one year from starting EPT,
the results were essentially identical to those we have
Table 1 Comparison of characteristics of women participating in the California Teachers Study mammographic density
substudy who were included in the analyses with those of participants who were excluded from the analyses
Characteristics Interviewed participants not included
in the current analysis (n = 720)
Interviewed participants included in the current
analysis (non-Hispanic white EPT quitters) (n = 284)
P values
At cohort enrollment
Age (mean ± SD) 49.9 ± 4.2 (range 40-60) 50.5 ± 3.8 (range 41-60) 0.07
BMI (kg/m2) 24.6 ± 4.8 (range 17-50) 24.7 ± 4.9 (range 17-47) 0.68
White (N (%)) 624 (87%) 284 (100%)
Nulliparous women (N (%)) 141 (20%) 63 (22%) 0.33
Menopausal status
Premenopausal 432 (60%) 155 (55%) 0.012
Perimenopausal 87 (12%) 55 (19%)
Postmenopausal 201 (28%) 74 (26%)
Ever had breast biopsy (N (%)) 108 (15%) 40 (14%) 0.71
Positive 1st degree family history of
breast cancer (N (%))
64 (9%) 37 (13%) 0.053
At mammogram substudy
enrollment
Age at interview (mean ± SD) 62 ± 4.0 (range 52-71) 62 ± 3.6 (range 53-72) 0.11
BMI (kg/m2) 26.2 ± 5.2 (range 17-49) 25.7 ± 5.0 (range 18-47) 0.16
Positive 1st degree family history of
breast cancer (N (%))
112 (16%) 51 (18%) 0.43
Number of mammograms in the past
10 years
8.8 ± 2.3 (range 2-20) 8.9 ± 2.2 (range 2-18) 0.59
At time of mammography evaluated
for density
Age at time of mammogram while
taking EPT
56 ± 4 (range 45-67)
Age at time of mammogram while off
EPT
60 ± 5 (range 49-71)
BMI at time of mammogram while
taking EPT
25.7 ± 5.2 (range 18-47)
BMI at time of mammogram while off
EPT
25.8 ± 5.0 (range 18-48)
Years on EPT at time of mammogram
while taking EPT
<1 year 15 (5%)
1- < 4 years 121 (43%)
4- < 7 years 112 (39%)
≥7 years 36 (13%)
Time interval between two
mammograms (years)
≤3 years 141 (50%)
4-5 years 106 (37%)
6-9 years 37 (13%)
EPT, estrogen and progestin combined therapy; BMI, body mass index.
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time of on-EPT mammogram did not change the results.
We did not observe any evidence of effect modification
by BMI at baseline or BMI change between the two
mammograms.Discussion
In this longitudinal study of EPT quitters, overall genetic
variation in the 30 hormone metabolism pathway genes
was not associated with density change. However, at the
gene-level, we found some evidence that two hormone
Table 2 Gene-level summary P values associated with
mammographic density change after quitting EPT use
Gene Number of
SNPs genotyped
Gene-level
association P value*
AKR1C4 1 0.44
AR 6 0.39
ARSC 2 0.02
COMT 21 0.14
CYP11A 12 0.64
CYP19A1 2 0.80
CYP1A1/CYP1A2 5 0.97
CYP1B1 15 0.61
CYP21A2 2 0.13
CYP2C9 16 0.73
CYP3A4 3 0.46
ESR1 13 0.81
ESR2 22 0.68
HSD17B1 5 0.11
HSD17B2 24 >0.99
HSD17B4 24 0.49
HSD17B5/AKR1C3 38 0.85
HSD3B1 4 0.14
HSD3B2 10 0.97
PGR 32 0.81
SHBG 13 0.60
SLCO1B1 (SLC21A6) 38 0.04
SRD5A1 24 0.80
SULT1A1/SULT1A2 6 0.26
SULT1E1 18 0.50
UGT1A8 43 0.99
UGT2B17 1 0.63
UGT2B7 5 0.52
*Based on the adaptive rank truncated product (ARTP) statistics. EPT, estrogen
and progestin combined therapy; SNP, single nucleotide polymorphisms.
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were associated with MD change after women quit EPT
use. The few SNPs previously proposed to be associated
with EPT-associated density change, including SNPs
in PGR (rs10895068) [24], AKR1C4 (rs17134592) [23],Table 3 SNPs that are statistically significantly associated wit
correcting for multiple testing*
SNP (major/minor allele) Gene Minor allele frequency
rs7489119 (C/A) SLCO1B1 0.041
rs5933863 (G/A) ARSC 0.15
*Based on linear regression model adjusting for age and BMI (kg/m2) at time of on-EPT
and mammographic density of on-EPT mammogram. Additive genetic model was use
within each gene was calculated using the methods by Conneely and Boehnke [33]. E
polymorphisms; SE, standard error; BMI, body mass index.CYP1B1 (rs1056836) [23], were not associated with MD
change in this study. Rs10895068 and rs17134592 were
genotyped in this study, and rs1056836 was tagged with
three SNPs in LD (r2 = 0.74-0.76). To our knowledge, this
study is the first to systematically investigate hormone me-
tabolism pathway genes as genetic determinants of longi-
tudinally assessed MD change after women quit EPT use.
Data from WHI and PEPI clinical trials have shown
that EPT use for one year increased MD by 3 to 7%
[10-12]. In a randomized trial, two-month suspension of
EPT decreased MD to a larger extent (by 2.8%) than was
observed in the comparison group who continued EPT
use [17]. However, in all studies, large interindividual
variation in the MD change was noted after introducing
[10-12] or stopping EPT use [17]. Increases and de-
creases in MD have been associated with higher and
lower, respectively, risk of breast cancer in a study of
women who were not using hormone therapy [19]. In
addition, in a nested case-control study within a breast
cancer prevention trial, decrease in MD was a good pre-
dictor of tamoxifen-induced reduction in breast cancer
risk [20]. Further, genetic variation in a tamoxifen me-
tabolizing enzyme CYP2D6 has been associated with
MD change following tamoxifen treatment [44]. Thus it
seems reasonable that understanding the genetic deter-
minants of the interindividual variability in MD changes
in response to EPT use or quitting can help predict
breast cancer risk in EPT users or former users.
Our finding that one SNP (rs7489119) in SLCO1B1
may be involved in determining EPT-related MD change
is novel and biologically plausible. SLCO1B1, also known
as SLC21A6, is a solute carrier organic anion transporter
gene expressed in the liver. SLCO1B1 transports a va-
riety of endogenous and exogenous substrates from the
blood into the hepatocytes [45], including estradiol-17β-
glucuronide and estrone-3-sulfate (E1S) [46,47]. E1S is a
major component of conjugated equine estrogens, the
estrogen component of the predominant EPT regimens
in the US (at least prior to 2002) [48]. Two [46,49] of
the three [46,49,50] experimental studies reported that
variant forms of SLCO1B1 showed reduced uptake of
E1S and estradiol glucuronide. Specifically, polymor-
phisms leading to amino acid changes within the
transmembrane-spanning domains such as rs56101265h EPT-associated mammographic density change after
N (WW/WV/VV) beta SE P PACT
¶
258/23/1 −4.22 1.25 0.0008 0.018
200/79/5 1.87 0.75 0.013 0.025
mammogram, time interval and BMI change between the two mammograms,
d. ¶Multiple testing corrected P value; PACT (P values adjusted for correlated tests)
PT, estrogen and progestin combined therapy; SNP, single nucleotide
Table 4 SNPs that are statistically significantly associated with EPT-associated mammographic density change in either nulliparous (n = 63) or parous (n = 219)
women after correcting for multiple testing at gene level¶
SNP Minor Nulliparous (n = 63) Parous (n = 219)
(major/minor allele) Gene allele frequency N (WW/WV/VV) Beta (SE) P PACT
* N (WW/WV/VV) Beta (SE) P PACT
* P for interaction†
rs2077647 (T/C) ESR1 0.49 18/30/15 3.92 (1.06) 0.0005 0.006 56/118/43 −0.40 (0.63) 0.53 >0.99 0.003
rs9605030 (C/T) COMT 0.14 40/21/2 4.47 (1.42) 0.0025 0.043 166/48/4 0.69 (0.88) 0.44 >0.99 0.011
rs5933863 (G/A) ARSC 0.15 46/17/0 1.26 (1.88) 0.51 0.75 152/62/5 2.00 (0.81) 0.014 0.027 0.82
¶Based on linear regression model adjusting for age and BMI (kg/m2) at time of on-EPT mammogram, time interval and BMI change between the two mammograms, and mammographic density of on-EPT mammogram.
Additive genetic model was used. *Multiple testing corrected P value; PACT (P values adjusted for correlated tests) within each gene was calculated using the methods by Conneely and Boehnke [33].
†P values for interaction
were not corrected for multiple testing. SNP, single nucleotide polymorphisms; EPT, estrogen and progestin combined therapy; SE, standard error; BMI, body mass index.
Lee
et
al.Breast
Cancer
Research
 (2014) 16:477 
Page
8
of
12
Lee et al. Breast Cancer Research  (2014) 16:477 Page 9 of 12(Phe73Leu), rs56061388 (Val82Ala), rs4149056 (Val174Ala),
and rs55901008 (Ile353Thr) [46,49] and those within
extracellular loop 5 such as rs56387224 (Asn432Asp),
rs72559748 (Asp462Gly), and rs59502379 (Gly488Ala) [49],
were shown to affect the uptake kinetics. The MAF of
rs4149056 (Val174Ala) was 0.14 in Europeans [49], but
MAFs of the rest were less than or equal to 0.02 [49].
Rs4149056 was associated with blood E1S levels in
Europeans [46]. However, rs4149056 was not in LD with
rs7489119 (r2 = 0.01) in European populations based on
HapMap data [51], and was not associated with MD
change in our study using imputed genotype data. The im-
putation certainty and info scores for rs4149056 were 0.98
and 0.92, respectively. These observations suggest that
rs4149056 is unlikely to be a causal variant of the observed
association for rs7489119. We could not check LD
between rs7489119 and the other functional SNPs in
SLCO1B1 because genotype data for these SNPs are not
publicly available or monomorphic in Europeans [35].
More recently, using an independent data from a breast
cancer case-control study nested within CTS, our group
reported that EPT use modified the effect of SLCO1B1
SNPs on breast cancer risk [29]. We found that rs4149013,
a SNP located near the 5’ end of SLCO1B1 with unknown
functional significance, was associated with breast cancer
risk, and this association was restricted to EPT users (odds
ratio (OR) = 2.3 per minor allele) [29]. This SNP did not
show an association with EPT-related MD change in
the current analysis, and is not in LD with rs7489119
(r2 = 0.003).
Arylsulfatase C (ARSC), also known as steroid sulfa-
tase (STS), is expressed in the liver and breast, and con-
verts E1S into biologically active E1 [52]. Rs5933863 is
located in 3’ UTR of ARSC. To our knowledge, no data
exist regarding the functional significance of rs5933863
or other SNPs in ARSC.
Our current finding that PGR genetic variation is not
associated with EPT-related MD change is consistent
with the results from our own previous report based on
PEPI trial data [15], although an earlier longitudinal
study based on EPIC data showed that rs10895068
(+331 G/A) of the two tested PGR SNPs showed an as-
sociation [24].
Our exploratory analysis in nulliparous women suggests
that ESR1 and COMT SNPs (rs2077647, and rs9605030,
respectively) may be associated with EPT-associated MD
changes in this subset. Although we had limited sample
size for this subset analysis and these observations may be
chance findings, our data are novel and warrant evaluation
in larger studies of nulliparous women, who have higher
MD [40,41] and higher breast cancer risk than parous
women [53]. It has been hypothesized that breast tissue
cells of nulliparous women may be subject to greater
damage from carcinogens than the cells of parous women[42], as nulliparous breast tissue cells have not undergone
parity-induced proliferation, differentiation, and involu-
tion [39].
After the publication of WHI trial results in 2002 [9],
EPT use markedly dropped in the US [54]; this was im-
mediately followed by decreases in breast cancer inci-
dence [26,55]. It was reported that the elevated breast
cancer risk in the WHI EPT group decreased rapidly
after terminating the intervention, and the hazard ratio
representing the risk of breast cancer associated with
EPT use became approximately 1.0 within two years of
cessation of exposure [56]. However, the large individual
variation in MD decrease after stopping hormone the-
rapy [18] suggests that the magnitude of risk reduction
after stopping EPT may vary. Given that individual cha-
racteristics of women (for example age, BMI, parity,
family history of breast cancer) are not related to the
variability in MD changes [18], our findings that genetic
factors may determine the amount of change in MD
after quitting EPT require confirmation in future stu-
dies. Further, whether these predictors of MD decline,
also predict an increase in MD when starting EPT, must
be verified. The clinical management guidelines pub-
lished in 2014 recommend using the lowest effective
dose for the shortest duration for management of me-
nopausal symptoms [57]. For women who consider this
therapy to curtail menopausal symptoms, it would be
beneficial to know whether they are at higher risk of ex-
periencing MD changes resulting from EPT use. Such
findings could help to identify a subgroup of women
who should avoid EPT use.
In this study we were able to comprehensively inves-
tigate hormone metabolism pathway genes as deter-
minants of EPT-related MD changes. A strength of our
study is that one experienced investigator estimated
MD in all of the mammograms using a standardized
and validated method; further, both sets of mammo-
grams from the same woman were evaluated within the
same batch. A limitation of our study is that we only
studied non-Hispanic white women. In addition, we did
not have a comparison group who continued to use
EPT or who never used EPT. Thus, it is possible that
the genetic predictors of change in MD that we identi-
fied may not be specifically associated with changes fol-
lowing cessation of EPT, but also associated with MD
reductions following aging.
Conclusions
Data from this longitudinal study of EPT quitters sug-
gest that genetic variation in two hormone metabolism
pathway genes, SLCO1B1 and ARSC, may be associated
with change in MD after women quit EPT use. Lar-
ger longitudinal studies are needed to confirm our
findings.
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